COMBINED HORMONAL CONTRACEPTIVES AND THE BREAST


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of the current data available in the literature on benign diseases of the breast and their role in the genesis of its cancer, on the effects of sex steroids on the physiological and pathophysiological processes occurring in the breast, on the role of combined oral contraceptives (COCs) in the risk of breast cancer and their effects on the course of benign diseases. Materials and methods. The review included the data of foreign and Russian papers published in the past 10 years and found in Pubmed on this topic. Results. The paper describes the specific features of benign breast diseases, their epidemiology, and their role in the genesis of malignant tumors and presents the effects of sex hormones on cellular homeostasis in the breast and the pathophysiology of cyclic mastalgia, as well as the results of multicenter studies evaluating the efficacy of combined hormonal contraceptives with drospirenone against symptoms, such as mastalgia and mastodynia. There are data on the safety of using COCs against the possible risk of cancer of the breast and its progressive benign diseases. Conclusion. Summarizing the literature data, it should be noted that the use of drospirenone-containing hormonal contraceptives is the pathophysiological basis for the treatment of cyclic mastalgia within premenstrual syndrome or as a separate entity. The results of the studies provide evidence that the long-term use of COCs reduces the incidence of benign diseases of the breast and does not increase the risk of its cancer.

Full Text

Restricted Access

About the authors

Kasyan Nikolaevna Victoria

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: gynendo-nkc@yandex.ru
MD, PhD, Associate Professor of Gynecology, Department of reproductive medicine and surgery Moscow 127473, Delegatskaya str. 20-1, Russia

References

  1. de Bastos M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M. et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst. Rev. 2014; (3): CD010813.
  2. Caserta D., Ralli E., Matteucci E., Bordi G., Mallozzi M., Moscarini M. Combined oral contraceptives: health benefits beyond contraception. Panminerva Med. 2014; 56(3): 233-44.
  3. Huber J.C., Bentz E.K., Ott J., Tempfer C.B. Non-contraceptive benefits of oral contraceptives. Expert Opin. Pharmacother. 2008; 9(13): 2317-25.
  4. Moorman P.G., Havrilesky L.J., Gierisch J.M., Coeytaux R.R., Lowery W.J., Peragallo Urrutia R. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J. Clin. Oncol. 2013; 31(33): 4188-98.
  5. Schindler A.E. Noncontraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7.
  6. Vessey M., Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br. J. Cancer. 2006; 95(3): 385-9.
  7. Vessey M., Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-83.
  8. Аксель Е.М. Заболеваемость и смертность от злокачественных новообразований органов женской репродуктивной системы в России. Онкогинекология. 2015; 1: 6-15.
  9. Globocan 2012. Cancer incidence and mortality worldwide: IARC cancer base № 11. Lyon, France: International Agency for Research on Cancer; 2013.
  10. Беспалов В.Г. Мастопатия и профилактика рака молочной железы. Terra Medica. 2007; 1: 44-7.
  11. Горяйнова Л.К. Дисгормональная дисплазия молочных желез у женщин (мастопатия). Поликлиника. 2010; 6: 136-42
  12. Овсянникова Т.В., Асриян Я.Б., Ардус Ф.А. Возможности терапии дисгормональной патологии молочных желез у женщин с гинекологическими заболеваниями. Русский медицинский журнал. 2008; 16(16): 1064-7.
  13. Пекарев О.Г., Васильев А.Н., Попова С.П., Пекарева Е.О. Мастопатия: новый взгляд на старую проблему глазами гинеколога. Акушерство и гинекология. 2010; 5: 73-8.
  14. Vogel V.G. Epidemiology, genetics and risk evaluation of postmenopausal women at risk of breast cancer. Menopause. 2008; 15(4): 782-9.
  15. Love S.M., Gelman R.S., Silen W. Sounding board. Fibrocystic «disease» of the breast-a nondisease? N. Engl. J. Med. 1982; 307(16): 1010-4.
  16. Fentiman I.S. The pathophysiology and therapy of benign breast disease. In: Fauser B.C., ed. Reproductive medicine: molecular, cellular and genetic fundamentals. Parthenon Publishing; 2003: 487-94.
  17. Olawaiye A., Withiam-Leitch M., Danakas G., Kahn K. Mastalgia: a review of management. J. Reprod. Med. 2005; 50(12): 933-9.
  18. Scurr J., Hedger W., Morris P., Brown N. The prevalence, severity, and impact of breast pain in the general population. Breast J. 2014; 20(5): 508-13.
  19. Gadducci A., Guerrieri M.E., Genazzani A.R. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecol. 2012; 64(1): 67-74.
  20. Корженкова Г.П. Фиброзно-кистозная мастопатия: вариант нормы или болезнь? Онкогинекология. 2013; 3: 46-55
  21. Сметник В.П., Коновалова В.Н., Леонова Н.Ю. Патофизиология и терапия доброкачественных заболеваний молочных желез: дискуссионные вопросы. Проблемы репродукции. 2009; 2009; 1: 93-9.
  22. Hughes L.E., Mansel R.E., Webster D.J.T. Aberrations of normal development and involution (ANDI): A new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet. 1987; 2(8571): 1316-9.
  23. Söderqvist G., Isaksson E., von Schoultz B., Carlström K., Tani E., Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am. J. Obstet. Gynecol. 1997; 176(1, Pt1): 123-8.
  24. Clarke R.B., Howell A., Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res. Treat. 1997; 45(2): 121-33.
  25. Sitruk-Ware R., Plu-Bureau G. Exogenous progestagens and the human breast. Maturitas. 2004; 49: 58-66.
  26. Anderson E. Cellular homeostasis and the breast. Maturitas. 2004; 49: 13-7.
  27. Chang K.J., Lee T.T., Linares-Cruz G., Fournier S., de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil. Steril. 1995; 63(4): 785-91.
  28. Laidlaw I.J., Clarke R.B., Howell A., Owen A.W., Potten C.S., Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 1995; 136(1): 164-71.
  29. Plu-Bureau G., Lee M.G., Thalabard J.C. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. Cancer Direct. Prevent. 1999; 23 4): 290-6.
  30. Mansel R.E., Webster D.J.T., Sweetland H.M. Breast pain and nodularity. In: Benign disorders and diseases of the breast. Elsevier; 2009: 107-39.
  31. Halaska M., Beles P., Gorkow C., Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: result of a placebo-controlled double-blind study. The Breast. 1999; 8: 175-81.
  32. Кузнецова И.В., Сумятина Л.В. Контрацептивная и лечебная эффективность «ярины» у женщин с предменструальным синдромом. Гинекология. 2004; 6(6): 310-2.
  33. Кузнецова И.В., Коновалов В.А. Современная терапия предменструального сондрома (обзор литературы). Гинекология. 2013; 15(3): 25-35.
  34. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.
  35. Пекарев О.Г., Майбородин И.В., Пекарева Е.О., Поздняков И.М., Попова С.П. Самопроизвольное родоразрешение пациенток с рубцом на матке после миомэктомии. Российский вестник акушера-гинеко-лога. 2012; 12(4): 93-8.
  36. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В. Эффективность и приемлемость применения дроспиренонсодержа-щего комбинированного орального контрацептива для терапии предменструального дисфорического расстройства. Доктор.Ру. Гинекология Эндокринология. 2013; 1: 48-52
  37. Sillem M. Yasminelle (R): a new low-dose combined oral con-traceptive containing drospirenone. Womens Health (London). 2006; 2(4): 551-9.
  38. Lawrie T.A., Helmerhorst F.M., Maitra N.K., Kulier R., Bloemenkamp K., Gülmezoglu A.M. Types of progestogens in combined oral contraception: effectiveness and side effects. Cochcrane Database Syst. Rev. 2011; (5): CD004861.
  39. Guang-Sheng F., Mei-Lu B., Li-Nan C., Xiao-Ming C., Zi-Rong H., Zi-Yan H. et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/ drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin. Drug Investig. 2010; 30(6): 387-96.
  40. Endrikat J.S., Milchev N.P., Kapamadzija A., Georgievska J., Gerlinger C., Schmidt W., Feroze S. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009; 79 (6): 428-32.
  41. Braendle W., Kuhl H., Mueck A., Birkhäuser M., Thaler C., Kiesel L., Neulen J. Does hormonal contraception increase the risk for tumors? Ther. Umsch. 2009; 66(2): 129-35.
  42. Burkman R.T. Oral contraceptives: current status. Clin. Obstet. Gynecol. 2001; 44(1): 62-72.
  43. Davidson N.E., Helzlsouer K.J. Good news about oral contraceptives. N. Engl. J. Med. 2002; 346(26): 2078-9.
  44. Hankinson S.E., Colditz G.A., Manson J.E., Willett W.C., Hunter D.J., Stampfer M.J., Speizer F.E. A prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States). Cancer Causes Control. 1997; 8(1): 65-72.
  45. Marchbanks P.A., McDonald J.A., Wilson H.G., Folger S.G., Mandel M.G., Daling J.R. et al. Oral contraceptives and the risk of breast cancer. N. Engl. J. Med. 2002; 346(26): 2025-32.
  46. Seeger H., Ruan X., Neubauer H., Mueck A.O. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm. Mol. Biol. Clin. Investig. 2011; 6(2): 211-4.
  47. Hannaford P.C., Selvaraj S., Elliott A.M., Angus V., Iversen L., Lee A.J. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007; 335(7621): 651.
  48. Thorbjarnardottir T., Olafsdottir E.J., Valdimarsdottir U.A., Olafsson O., Tryggvadottir L. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Acta Oncol. 2014; 53(6): 752-8.
  49. Grabrick D.M., Hartmann L.C., Cerhan J.R., Vierkant R.A., Therneau T.M., Vachon C.M. et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000; 284(4): 1791-8.
  50. Medical eligibility criteria for contraceptive use. 5th ed. WHO; 2015. 276p. Available at: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies